Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Johnson & Johnson digs slightly deeper for Guidant

This article was originally published in Clinica

Executive Summary

After more than a week of frenzied speculation, Johnson & Johnson and Guidant have emerged from the negotiating room with a $24bn deal for the former to acquire the latter. As Clinica went to press this week, Guidant agreed to a $76 per share cash and stock bid, just $1 up on the $75 offer that the two companies had been widely reported to be stuck on. The acquisition's fully diluted equity value is $25.4bn, and its net acquisition cost $23.9bn as of December 15.

Topics

UsernamePublicRestriction

Register

MT060519

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel